The Structural Genomics Consortium at The Neuro (SGC Neuro) focuses on the “Dark Genome” targets, under-studied genes implicated in neurodegenerative disorders, and creating tools such as brain cells differentiated from genetically modified induced pluripotent stem cell lines and commercial antibody profiling through the 

The Structural Genomics Consortium at The Neuro (SGC Neuro) focuses on the “Dark Genome” targets, under-studied genes implicated in neurodegenerative disorders, and creating tools such as brain cells differentiated from genetically modified induced pluripotent stem cell lines and commercial antibody profiling through the YCharOS platform. The goal is to understand whether or/and how these genes and the proteins they encode contribute to pathology, and most importantly drive a fundamental shift in neurodegenerative disease research by uncovering new mechanisms and pathways in disease biology and delivering new targets for therapy.

The SGC Neuro laboratories, under the direction of Dr. Edward Fon, are housed at the Montreal Neurological Institute and the McIntyre Medical Sciences Building, which are all affiliated with the departments of Neurology and Neurosurgery, Pharmacology and Therapeutics as well as the Human Genetics at McGill University.